Market Newsdesk

Wagner Corporation Collaborates with Virgin Orbit to Bring National Air-Launch Capability to Australia

Wagner Corporation and Virgin Orbit have signed an agreement to assess a potential LauncherOne demonstration mission from the Toowoomba Wellcamp Airport.

LONG BEACH, Calif. & WELLCAMP, Australia–(BUSINESS WIRE)–
Virgin Orbit (Nasdaq: VORB), a leading launch provider, announced today that it has signed a Memorandum of Understanding (MOU) with Wagner Corporation, one of the region’s most successful privately-owned companies and proprietor of the Toowoomba Wellcamp Airport and Business Park in Queensland, Australia. The agreement will allow the companies to begin the process of implementing a national launch capability from Australia, with the goal of providing satellite launch services from the Toowoomba Wellcamp Airport using Virgin Orbit’s LauncherOne System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005713/en/

In pursuing their joint mission to revolutionize the space industry in Australia, Virgin Orbit and Wagner Corporation are exploring the potential to certify Toowoomba Wellcamp Airport as a national spaceport to perform an orbital launch demonstration as early as 2024. The cooperative effort is designed to catalyze the maturing Australian small satellite and space solutions market, stimulate local economic growth, support commercial and civil endeavors and provide Australian defense and government with a flexible, responsive and flight-proven national launch capability in support of a wide range of mission applications.

Drawing on regional and local expertise from Wagner Corporation and on launch and mission expertise from Virgin Orbit, this collaboration will focus its initial efforts on tailoring LauncherOne operations from Toowoomba Wellcamp Airport to comply with Australian launch licensing regulatory requirements and spaceport-specific operations. Both companies aim to develop a roadmap for how LauncherOne’s Mobile Ground Support Equipment and other infrastructure could be built and staged at Toowoomba Wellcamp Airport to provide Australia with a resilient and proven national launch capability, and ultimately transform the Toowoomba Wellcamp Airport into Australia’s leading space industry innovation center. The roadmap will seek to lay out the steps required to enable the first flights of LauncherOne to occur from Australia in as soon as 16-18 months.

“At Virgin Orbit, we look to a day soon when satellites fly to space from Australia,” said Virgin Orbit CEO Dan Hart. “We’re thrilled to be working alongside Wagner Corporation, one of the region’s most successful privately-owned companies, to bring the first national orbital launch to Australia. Combining their deep knowledge of infrastructure development and affinity for aerospace with our proven, responsive LauncherOne system, we have all the ingredients to bring spaceflight to Queensland.”

Wagner Corporation Chairman John Wagner said, “Virgin Orbit’s selection of Toowoomba Wellcamp Airport for its newest national spaceport, to perform satellite launches, was extremely exciting and a further significant boost for Queensland and Australia. Wellcamp Airport and Business Park is on track to becoming one of the most sustainable carbon neutral destinations internationally. Virgin Orbit will join Boeing and other international companies as part of Wellcamp’s new world-class, Aerospace and Defence Precinct and Campus, with Stage 1 due for completion by the end of 2024. Attracting global companies such as Virgin Orbit is recognition of the strategic advantages that Wellcamp Airport and the Aerospace and Defence Precinct offers, and we are looking forward to a long and prosperous relationship.”

“Australian space is open for business,” said James Brown, CEO Space Industry Association of Australia (SIAA). “We are excited to see a leading global launch company working with Australian industry to develop an agile, responsive solution for space clients.”

About Virgin Orbit

Virgin Orbit (Nasdaq: VORB) operates one of the most flexible and responsive space launch systems ever built. Founded by Sir Richard Branson in 2017, the company began commercial service in 2021, and has already delivered commercial, civil, national security, and international satellites into orbit. Virgin Orbit’s LauncherOne rockets are designed and manufactured in Long Beach, California, and are air-launched from a modified 747-400 carrier aircraft that allows Virgin Orbit to operate from locations all over the world in order to best serve each customer’s needs. Learn more at www.virginorbit.com and visit us on LinkedIn, on Twitter @virginorbit, and on Instagram @virgin.orbit.

About Wagner Corporation

The family-owned Wagner Corporation (ASX: WGN) has a reputation for intrepid thinking, quality delivery, trusted partnerships, and a proven track-record for purpose-built infrastructure and new product design. Wagner Corporation and its associated entities are the owner of the Toowoomba Wellcamp Airport and Wellcamp Aerospace and Defence Precinct in Queensland, Australia. To learn more, visit www.wagnercorporation.com.au or contact [email protected].

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the Company’s ability to access sources of capital; its ability to grow market share in the developing space economy; market acceptance of its current and planned products and services and ability to achieve sufficient production volumes, as well as the factors, risks and uncertainties included in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022, as well as in the Company’s subsequent filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Information section of the Company’s website at www.virginorbit.com. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Virgin Orbit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Virgin Orbit gives no assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005713/en/

MEDIA INQUIRIES:

[email protected]

Alison Patch

[email protected]

+1-949-616-2504

KEYWORDS: California Australia/Oceania Australia United States North America

INDUSTRY KEYWORDS: Air Technology Satellite Transport Aerospace Manufacturing

MEDIA:

Logo

Photo

Courtesy of Virgin Orbit

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–
Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including the existing facility and all related personnel (the “Manufacturing Business Unit”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005651/en/

Under the terms of an asset purchase agreement between Celyad Oncology and Cellistic, Cellistic agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for a total consideration of €6 million. Celyad Oncology’s experienced manufacturing team will join Cellistic. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year.

“We at Cellistic are incredibly excited to welcome this uniquely talented team into our organization,” said Stefan Braam, founder and CEO of Cellistic. “We’re bringing aboard a group of people whose passion and capabilities align incredibly well with our vision for the future of cell therapy. As a joined force, we have the talent and resources to further accelerate work on our proprietary platforms and the capability to enable Cellistic’s partners to bring iPSC-based allogeneic cell therapies to patients faster.”

Michel Lussier, co-founder and interim CEO of Celyad Oncology, said, “We have focused our efforts on an allogeneic approach for the past few years and our manufacturing facility and staff has been a key element to enable many of our past trials, but has been underutilized in recent years as we mainly used the facility for our autologous candidates. Our current allogeneic programs are better suited for outsourced manufacturing. Through existing materials manufactured at Celyad, we have ensured the means to continue our clinical programs with cryopreserved cells until 2024. Based on this strategy, we are confident that this decision to transfer our manufacturing facility and the staff to Cellistic, who is the perfect company for such an agreement and will allow us to further execute on our business goals in the future.”

Cellistic will invest substantial capital into the newly acquired 11,000 square foot facility, which will be optimized for its iPSC-based allogeneic cell therapy platforms and processes creating the world’s first purpose-built facility to support customers from cell reprogramming and master cell banking through clinical trial material manufacturing. A team of more than 30 manufacturing, quality and related personnel from Celyad Oncology, all with substantial cell therapy manufacturing and immune-oncology experience, will join Cellistic as part of this transaction.

Celyad Oncology will provide additional guidance on the future business strategy of the Company in the fourth quarter of this year.

About Cellistic

Launched in April 2022 as a subsidiary of Ncardia, Cellistic™ specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia’s scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale. For more information, visit www.cellistic.com.

About Ncardia

Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies in drug discovery to accelerate their development processes through the integration of human iPSC technologies. For more information, visit www.ncardia.com.

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Celyad Oncology Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the expected closing of the transaction. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005651/en/

Cellistic Investor and Media Contact:

[email protected]

Celyad Oncology Investor and Media Contact:

Sara Zelkovic

Communications & Investor Relations Director

Celyad Oncology

[email protected]

KEYWORDS: Belgium Europe United States North America

INDUSTRY KEYWORDS: Health Stem Cells Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Logo

CORRECTING and REPLACING A Next Generation of Smartsheet Aligned: Introducing Enhanced Channel Program Focused on Rewarding Partners for Deeper Platform Investments

New program structure and benefits will recognize partner expertise, performance, and achievement with Smartsheet’s work management platform

BELLEVUE, Wash.–(BUSINESS WIRE)–
Second paragraph, second sentence of release should read: “In fact, annual bookings led by partners has grown 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet. (instead of “In fact, annual bookings led by partners has grown to 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet.).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005730/en/

The updated release reads:

A NEXT GENERATION OF SMARTSHEET ALIGNED: INTRODUCING ENHANCED CHANNEL PROGRAM FOCUSED ON REWARDING PARTNERS FOR DEEPER PLATFORM INVESTMENTS

New program structure and benefits will recognize partner expertise, performance, and achievement with Smartsheet’s work management platform

Smartsheet, the enterprise platform for dynamic work, today shared how channel partners can unlock more through the Smartsheet Aligned program starting in February 2023. During the 2022 Global Partner Summit, the company unveiled the new program structure, which will recognize and reward over 800 global partners with tailored benefits allowing them to differentiate their value-add and promote the extensive investments they have made in Smartsheet.

“Smartsheet partners have played a critical role in the growth of our business, from extending our sales and marketing reach to expanding our professional services capabilities. In fact, annual bookings led by partners has grown 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet. “As customer requests for increasingly complex solutions continued to grow, it was imperative that our program evolve and offer enterprise-grade benefits to our partners so they can continue to provide best-in-class service for our customers. With the new structure, Smartsheet Aligned will be significantly more robust and focused on complex solution building than anyone else in the collaborative work management market.”

“The evolving nature of the channel ecosystem, combined with the increasing complexity of customer needs, is blurring traditional partner types and roles. We rely on our partners’ sector and regional expertise to not only reach a diverse range of potential customers, but to provide valuable consultancy,” said Mads Nielsen, Regional Channel Leader, APJ, Smartsheet.

Building on this leadership, the new Smartsheet Aligned program will provide specialized paths for partners to grow their businesses based on the unique value they provide Smartsheet customers. Partners like Global PMO and WORK BOLD can earn tiered benefits based on their partnership, performance, and capabilities, including:

• New custom role-based training and solutions certifications designed specifically for upskilling Smartsheet Aligned partners in addition to ongoing sales and technical training;
• Expanded financial discounts and rebates including differentiated incentives that provide a competitive market advantage;
• New marketing and demand generation resources to raise awareness of their business and drive net new opportunities; and
• Access to world-class technical enablement resources including pre- and post- sales experts to support partners with the delivery of complex Smartsheet solutions.

“The next phase of the Smartsheet Aligned program will have a two-fold benefit for us. It’ll boost Smartsheet’s presence in Australia and New Zealand while also improving the quality of Smartsheet’s relationship with the partners, and in turn, their clients. As Smartsheet’s biggest partner in the region, we’re really excited about the sales, marketing, and engagement possibilities that this opens up. Can’t wait to try it out,” said Iain Elliott, Chief Technology Officer and Atturra Data & Integration – Smartsheet Platinum Partner.

At the Global Partner Summit, partners will preview the new program structure, learn about new products, and network with others from around the world. Smartsheet and the partner community will also recognize eight partners for their achievements in standout sales and customer excellence. This year’s winners are:

• Americas Partner of the Year, Optimum Consulting, for the strongest growth across Smartsheet’s North and South American partner community;
• APAC Partner of the Year,Attura, for the strongest growth and capabilities across Smartsheet’s APAC partner community;
• EMEA Partner of the Year, Cheetah Transformation, for the strongest growth and capabilities across Smartsheet’s EMEA partner community;
• Channel Hero of the Year, Productive Project Solutions, for providing the greatest assistance to other partners in the Smartsheet Channel ecosystem;
• Rookie of the Year, Prime Consulting Group, for the strongest growth and capabilities within the first calendar year as a registered Smartsheet partner;
• Government Partner of the Year, M2 Strategy, for the strongest ARR growth across the private and public sector; and
• Brandfolder Partner of the Year, Getty Images, for the strongest growth and capabilities across the Brandfolder partner community.

Additionally, at the Summit, Smartsheet will select a winner for Solution Spotlight of the Year, which recognizes the partner whose solution created the biggest impact, whose ingenuity best addresses customer needs, and who can most readily scale solutions to other customer accounts.

Learn more about how to be a part of the Smartsheet Aligned ecosystem here.

About Smartsheet

Smartsheet (NYSE: SMAR) is the enterprise platform for dynamic work. By aligning people and technology so organizations can move faster and drive innovation, Smartsheet enables its millions of users to achieve more. Visit www.smartsheet.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005730/en/

Chrissy Vaughn

[email protected]

KEYWORDS: Washington North America United States Australia Australia/Oceania New Zealand

INDUSTRY KEYWORDS: Software Technology Consulting Professional Services

MEDIA:

Logo

Photo

Starting in February 2023, the Smartsheet Aligned program will recognize and reward over 800 global partners with tailored benefits allowing them to differentiate their value-add and promote the extensive investments they have made in Smartsheet. (Graphic: Business Wire)

Virios Therapeutics, Inc. Announces Pricing of Public Offering

ATLANTA–(BUSINESS WIRE)–
Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million shares of common stock at the public offering price less discounts and commissions, to cover over-allotments. The offering is expected to close on September 22, 2022, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 and for working capital and general corporate purposes.

ThinkEquity is acting as sole book-running manager for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-263700), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 18, 2022 and declared effective on April 28, 2022. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology.

Our lead development candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. The Company is pursuing a second development candidate, IMC-2 (valacyclovir and celecoxib), as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID, otherwise known as Post-Acute Sequelae of COVID-19.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Virios Therapeutics’ product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005894/en/

[email protected]

PCG Advisory

Kirin Smith

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Other Health

MEDIA:

Logo

CORRECTING and REPLACING A Next Generation of Smartsheet Aligned: Introducing Enhanced Channel Program Focused on Rewarding Partners for Deeper Platform Investments

New program structure and benefits will recognize partner expertise, performance, and achievement with Smartsheet’s work management platform

BELLEVUE, Wash.–(BUSINESS WIRE)–
Second paragraph, second sentence of release should read: “In fact, annual bookings led by partners has grown 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet. (instead of “In fact, annual bookings led by partners has grown to 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet.).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005718/en/

The updated release reads:

A NEXT GENERATION OF SMARTSHEET ALIGNED: INTRODUCING ENHANCED CHANNEL PROGRAM FOCUSED ON REWARDING PARTNERS FOR DEEPER PLATFORM INVESTMENTS

New program structure and benefits will recognize partner expertise, performance, and achievement with Smartsheet’s work management platform

Smartsheet, the enterprise platform for dynamic work, today shared how channel partners can unlock more through the Smartsheet Aligned program starting in February 2023. During the 2022 Global Partner Summit, the company unveiled the new program structure, which will recognize and reward over 800 global partners with tailored benefits allowing them to differentiate their value-add and promote the extensive investments they have made in Smartsheet.

“Smartsheet partners have played a critical role in the growth of our business, from extending our sales and marketing reach to expanding our professional services capabilities. In fact, annual bookings led by partners has grown 59% since launching the program three years ago,” said Steve Stewart, Global Head of Channel at Smartsheet. “As customer requests for increasingly complex solutions continued to grow, it was imperative that our program evolve and offer enterprise-grade benefits to our partners so they can continue to provide best-in-class service for our customers. With the new structure, Smartsheet Aligned will be significantly more robust and focused on complex solution building than anyone else in the collaborative work management market.”

Building on this leadership, the new Smartsheet Aligned program will provide specialized paths for partners to grow their businesses based on the unique value they provide Smartsheet customers. Partners like Global PMO and WORK BOLD can earn tiered benefits based on their partnership, performance, and capabilities, including:

• New custom role-based training and solutions certifications designed specifically for upskilling Smartsheet Aligned partners in addition to ongoing sales and technical training;
• Expanded financial discounts and rebates including differentiated incentives that provide a competitive market advantage;
• New marketing and demand generation resources to raise awareness of their business and drive net new opportunities; and
• Access to world-class technical enablement resources including pre- and post- sales experts to support partners with the delivery of complex Smartsheet solutions.

“Smartsheet’s world-class partner program coupled with the tremendous growth of the CWM market has helped us quickly grow our business over the past four years,” said Sebastian Paasch, Managing Director at AMX. “From the increased visibility with Smartsheet’s customer base to the recognition around our investments in their industry-leading platform, I look forward to building on our partnership in the next phase of the Smartsheet Aligned program.”

At the Global Partner Summit, partners will preview the new program structure, learn about new products, and network with others from around the world. Smartsheet and the partner community will also recognize eight partners for their achievements in standout sales and customer excellence. This year’s winners are:

• Americas Partner of the Year, Optimum Consulting, for the strongest growth across Smartsheet’s North and South American partner community;
• APAC Partner of the Year,Attura, for the strongest growth and capabilities across Smartsheet’s APAC partner community;
• EMEA Partner of the Year, Cheetah Transformation, for the strongest growth and capabilities across Smartsheet’s EMEA partner community;
• Channel Hero of the Year, Productive Project Solutions, for providing the greatest assistance to other partners in the Smartsheet Channel ecosystem;
• Rookie of the Year, Prime Consulting Group, for the strongest growth and capabilities within the first calendar year as a registered Smartsheet partner;
• Government Partner of the Year, M2 Strategy, for the strongest ARR growth across the private and public sector; and
• Brandfolder Partner of the Year, Getty Images, for the strongest growth and capabilities across the Brandfolder partner community.

Additionally, at the Summit, Smartsheet will select a winner for Solution Spotlight of the Year, which recognizes the partner whose solution created the biggest impact, whose ingenuity best addresses customer needs, and who can most readily scale solutions to other customer accounts.

Learn more about how to be a part of the Smartsheet Aligned ecosystem here.

About Smartsheet

Smartsheet (NYSE: SMAR) is the enterprise platform for dynamic work. By aligning people and technology so organizations can move faster and drive innovation, Smartsheet enables its millions of users to achieve more. Visit www.smartsheet.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005718/en/

Chrissy Vaughn

[email protected]

KEYWORDS: Washington Switzerland Austria Germany North America Europe United States Ireland United Kingdom

INDUSTRY KEYWORDS: Other Professional Services Software Internet Marketing Data Management Communications Professional Services Technology

MEDIA:

Logo

Photo

Starting in February 2023, the new Smartsheet Aligned program will recognize and reward over 800 global partners with tailored benefits allowing them to differentiate their value-add and promote the extensive investments they have made in Smartsheet. (Graphic: Business Wire)

Bachoco Ad Hoc Committee Publishes Fairness Opinion and Communicates Position regarding Price of Potential Voluntary Tender Offer for Bachoco Shares

CELAYA, Mexico & GUANAJUATO, Mexico–(BUSINESS WIRE)–
Industrias Bachoco S.A.B. de C.V. (“Bachoco” or the “Company”) (NYSE: IBA; BMV: BACHOCO), announces that the members of its ad hoc committee met today regarding the intention of certain shareholders of Bachoco to make a voluntary tender offer to purchase all of Bachoco’s outstanding publicly owned shares not currently owned by such shareholders, through a special purpose vehicle (the “offeror”) for a cash purchase price of $81.66 Mexican pesos per share (the “offer price”), as previously announced on March 25, 2022 (such offer, the “offer” or “potential offer” as the context requires).

In April 2022, the ad hoc committee was formed, comprised exclusively of independent members of Bachoco’s board of directors (the “Board”), in connection with the aforementioned potential offer. The ad hoc committee engaged FTI Capital Advisors, LLC (“FTICA”), a wholly owned subsidiary of FTI Consulting, Inc. (NYSE: FCN), as an independent expert, to render its opinion to the Board as to whether the offer price to be paid by the offeror in the potential offer is fair, from a financial point of view, to the holders of shares of Bachoco’s Series B common stock, including any such shares represented by American Depositary Shares (collectively, the “Shares”), other than those held by Bachoco, the offeror or its affiliates (“excluded shares”). The ad hoc committee held a follow-up meeting on June 17, 2022, at which representatives of FTICA presented their preliminary perspectives as of the date of that meeting, while awaiting the commencement of the offer. On September 19, 2022, the ad hoc committee held a meeting at which representatives of FTICA rendered FTICA’s opinion as of the date of such meeting, as subsequently confirmed in writing on and as of such date. Given the delay in the commencement of the offer, the ad hoc committee considered that it was prudent and consistent with Bachoco’s historical transparency and corporate integrity to publish FTICA’s opinion and communicate it to the public.

Consequently, today, the ad hoc committee received FTICA’s written opinion, a copy of which is attached to this press release. Subject to the qualifications and assumptions on which it is based and the exceptions and limitations set forth therein, FTICA’s opinion states that it is of the opinion, as of the date hereof, that the offer price to be paid by the offeror in the potential offer is fair, from a financial point of view, to the holders of Shares, other than excluded shares. FTICA expressed no view as to, and FTICA’s opinion does not address, any other terms or other aspects or implications of the potential offer, and the foregoing description of FTICA’s opinion is qualified in its entirety by reference to the full text of its opinion, a copy of which is attached hereto.

Based on FTICA’s opinion, Bachoco’s ad hoc committee considers the offer price, as announced on March 25, 2022, to be reasonable from a financial point of view, and therefore fair, to the Company’s shareholders and will inform the full board of directors of the Company so that the latter, in turn, may issue its opinion, pursuant to the provisions of Article 101 of the Ley del Mercado de Valores (the “Mexican Securities Market Law”) and other applicable provisions.

In addition, the members of the ad hoc committee consider that the decision of a shareholder as to whether or not to tender its shares owned in Bachoco pursuant to the potential offer, if launched and, if so, how many shares to tender, is a personal investment decision based upon such individual shareholder’s particular circumstances. Accordingly, each shareholder is urged to make its own decision as to whether to tender its shares in the potential offer and, if so, how many shares to tender, based on all available information, including the shareholder’s investment objectives, the recent market prices of the relevant shares, the shareholder’s own views as to Bachoco’s prospects and outlook and any other factors that the shareholder deems relevant to its investment decision.

As required by Mexican law, a copy of FTICA’s opinion is attached hereto, with the understanding that the Company’s shareholders should review the attached opinion in its entirety, including the qualifications and assumptions on which it is based and the exceptions and limitations set forth therein, and await the determination of the full board before making any decision with respect to the potential offer.

This press release and exhibit can be downloaded from the SEC website at www.sec.gov and can also be found on Bachoco’s website at https://corporativo.bachoco.com.mx/inversionistas/.

COMPANY DESCRIPTION. Industrias Bachoco is a leader in the poultry industry in Mexico and one of the largest poultry companies in the world. The Company was founded in 1952, and began trading on the Mexican Stock Exchange and the New York Exchange in 1997. Corporate offices are located in Celaya, Mexico. Bachoco is vertically integrated; its main business lines are: chicken, eggs, balanced feed, pork, among other products. It has more than 1,000 facilities organized into 9 production complexes and 80 distribution centers in Mexico and a production complex in the United States. It currently generates more than 29,000 direct jobs. Bachoco has the following ratings: “AAA (MEX)”, the highest rating assigned by Fitch México, S.A. de C.V.; and “HR AAA”, which means that the Issuer or the Issue is of the highest credit quality and was granted by HR Ratings de México, S.A. de C.V.

DISCLAIMER. The document contains information that could be deemed forward-looking statements regarding expected future events and results of the Company. The statements reflect management’s current beliefs based on currently available information and are not guarantees of future performance and are based on our estimates and assumptions that are subject to risks and uncertainties, including those described in the Annual Information form, which could cause actual results to differ materially from the forward-looking statements contained herein. These risks and uncertainties include risks associated with ownership in the poultry industry, competition for investments in the poultry industry, shareholder liability, government regulation, and environmental matters. Accordingly, there can be no assurance that actual results will be consistent with these forward-looking statements. Except as required by applicable law, Industrias Bachoco, S.A.B. de C.V. undertakes no obligation to publicly update or revise any forward-looking statements.

This press release is not an offer to sell securities in the United States, Mexico, or elsewhere. The securities may not be offered or sold in the United States, Mexico, or any other jurisdiction without registration or an exemption from registration. Any public offering of securities in the United States or Mexico must be made through the preparation of a prospectus or prospectus.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005459/en/

Investor Relations Area

Phone:(461)6183555

Mail: [email protected]

KEYWORDS: New York Mexico United States Central America North America

INDUSTRY KEYWORDS: Retail Agriculture Natural Resources Food/Beverage

MEDIA:

Posted on September 19, 2022 9:19 pm

Curis Announces Date for the 2nd Annual VISTA Symposium

PR Newswire

Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022

Symposium hosted by Randolph Noelle, Ph.D.

LEXINGTON, Mass.
, Sept. 19, 2022 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the 2^nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET.

The event will be hosted by Randolph Noelle, Ph.D., Active Emeritus Professor of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth. Global leaders in immuno-oncology will gather at the Symposium to discuss the VISTA checkpoint, its role in cancer, and the latest VISTA research and therapeutic development.

“Curis is pleased to continue its sponsorship of the Annual VISTA Symposium,” said James Dentzer, President and Chief Executive Officer of Curis. “As the global leader in VISTA development, we are honored to provide a forum for discussing the progress we’re seeing with CI-8993, our own VISTA program, as well as programs from other companies and academic labs, as we collectively advance the forefront of VISTA research and development for the benefit of patients living with cancer.”

The virtual event features agenda topics including:

• VISTA Biology
• Biology Overview
• VISTA ligands and counterreceptors
• Role of VISTA in Tumor Immune Evasion

• VISTA Targeting
• The PK/PD complexities of target mediated disposition
• PET Imaging of VISTA targeting
• Clinical Opportunities and Questions
• Biomarkers, pathways and tumor subsets
• Anti-VISTA antibody in combination with radiation therapy
• Translational immunology in cutaneous malignancies
• Anti-VISTA Therapeutic Strategies

To learn more about the symposium and register to attend, please visit https://bit.ly/VISTA22.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as non-Hodgkin’s lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with AML and MDS, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax and expansion phase (Phase 2a), and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for the development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’s website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-announces-date-for-the-2nd-annual-vista-symposium-301627719.html

SOURCE Curis, Inc.